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Objectives 
After completion of this program, the reader should be able to: 
1. Discuss the background and origin of the Zika virus, 
including where the Zika virus has become endemic 
in the United States. 
2. Identify risk factors for contracting the Zika virus and 
its common routes of transmission. 
3. Recognize the signs and symptoms of the Zika virus. 
4. Prepare an appropriate plan to manage patients pre-
senting with Zika virus, including diagnostic testing, 
treatment and counseling points. 
5. Explain the logic behind the current investigational 
vaccines targeted against the Zika virus. 
Abstract 
The Zika virus has become a growing concern as a global 
pandemic. Since being identified in Uganda in 1947, the virus 
has spread around the world, recently emerging in South 
America with a great impact on Brazil. As of 2016, Zika has 
made its appearance in the United States and is now actively 
being transmitted in Florida. The virus is a mosquito-
vectored flavivirus primarily transmitted by the Aedes mos-
quito which infects a human through biting. Transmission 
through sexual intercourse is also possible as well as trans-
mission from a pregnant woman to her fetus. This latter form 
of transmission presents the primary problem with the Zika 
virus; transmission to the fetus can cause microcephaly as 
well as other brain and developmental problems. Proper pre-
cautions should be taken based on these identified modes of 
transmission. Symptoms of Zika are similar to flu-like symp-
toms, such as low-grade fever, muscle pain and headache. 
About 20 percent of patients that come in contact with the 
Zika virus will originally present as asymptomatic and will 
not display symptoms until almost two weeks after initial 
contact with the virus. Zika virus can remain in the blood for 
about a week, but can remain in the semen for months. There 
are a number of methods used to detect the Zika virus-
urine, blood or semen samples may be used to assess if a pa-
tient is infected. 
Key Terms 
Aedes; Centers for Disease Control and Prevention (U.S.); 
Diagnostic Tests; Fetus; Flavivirus; Florida; Microcephaly; 
Public Health; Sexual Partners; Vaccines; Zika Virus 
Introduction 
The Zika virus was originally identified in Uganda in 194 7. It 
has since spread around the world as two main strains, Asian 
and African, distinguishable by detailed analysis of the ribo-
nucleic acid (RNA) sequence.1 This difference in sequence 
relates to a variation in availability for potential glycosyla-
tion sites in the virus. The Asian strain is responsible for the 
outbreaks seen in Brazil and the United States, after travel-
ling through Pacific Island countries such as Malaysia (1969), 
Philippines (2012) and Easter Island (2014). In late 2014 
and early 2015, reports to the Brazilian Ministry of Health of 
an "acute exanthematic disease" began following the 2014 
Federation Internationale de Football Association (FIFA) 
World Cup, and, in March 2015, the Zika virus was isolated in 
patients in various regions of BraziJ.2 By May, the Brazilian 
Ministry of Health recognized local transmission of the Zika 
virus. In September, reports of microcephaly began to sur-
face, and on Oct. 23, 2015, the Brazilian Ministry of Health 
reported the occurrences to the World Health Organization. 
As the link between Zika virus and microcephaly became 
more apparent, the Brazilian Ministry of Health published 
guidelines for the management of microcephaly. There were 
an estimated 440,000 to 1,300,000 cases of Zika in Brazil in 
2015 alone, and 508 cases of microcephaly were confirmed 
by February 2016. 
As of 2016, reports of Zika virus spread to the United States, 
significantly increasing awareness of the disease. On Jan. 15, 
2016, the Centers for Disease Control and Prevention (CDC) 
released a health alert warning travelers and health care pro-
viders to be vigilant for the signs and symptoms of the Zika 
virus as travel-associated cases had already been reported in 
travelers returning to the United States.3 Since then, there 
has been a rise in cases in the United States, most notably in 
California, Florida, New York and Texas, with 4,389 travel-
associated cases reported as of Dec. 7, 2016.4 As of the same 
date, 185 locally acquired cases have been reported in the 
United States: 184 in Florida and one in Texas. The first re-
ports of local transmission came in late July from Miami, 
Florida, where Zika virus was isolated in four patients, which 
was likely caused by local Aedes aegypti mosquito bites, as 
the patients had not recently traveled outside of the United 
States.5 Territories of the United States have also reported 
locally acquired cases: 32,848 cases in Puerto Rico, 57 cases 
in American Samoa and 807 cases in the Virgin Islands. 
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Health care professionals and researchers have worked to 
gather as much information about the disease as possible, in 
order to inform the public about proper precautions.6 In 
addition, possible treatments and vaccines are currently in 
development. New information about the Zika virus is con-
stantly being discovered, and the imperative task of keeping 
the public informed has become an emerging role of health 
care professionals. 
Etiology and Transmission 
The Zika virus is a mosquito-vectored flavivirus which uses 
several mechanisms to alter host cellular pathways to favor 
viral replication.7 Transmission of the Zika virus can occur 
through several mechanisms: receiving a bite from an infect-
ed mosquito, vertical transmission from mother to child and 
transmission through sexual activity.6 Less commonly, the 
Zika virus may be transmitted via blood transfusion or 
through laboratory exposure, though these are typically not a 
concern in the general population. There have not been any 
confirmed cases of transmission via blood transfusion in the 
United States, though there have been cases reported in Bra-
zil. Additionally, the virus has been identified in blood donors 
in French Polynesia during several outbreaks. In one case 
study, spread of the virus through sweat and tears was also 
identified as a possible route oftransmission.s 
Transmission through the bite of a mosquito is the primary 
mode of transmission associated with the Zika virus. 6 Mos-
quitos of the Aedes genus may be infected with the virus, 
specifically the Aedes aegypti and Aedes albopictus species. 
These species of mosquito are primary reservoirs for the 
virus and can transmit other tropical diseases such as den-
gue fever and chikungunya. An infected mosquito can trans-
mit the virus to a human through a bite. Likewise, a mosquito 
may also become infected after biting a human infected with 
the Zika virus. In turn, the newly infected mosquito may 
spread the virus to any other human it bites. These mosqui-
tos are aggressive daytime biters, though biting, and there-
fore transmission, is also possible at night. 
Studies have been conducted that demonstrate vertical 
transmission as a possible mechanism of survival of the Zika 
virus in the Aedes aegypti mosquito.9 This is important when 
considering environments that act as potential breeding 
grounds for mosquitos. For instance, the Aedes mosquito 
often lays eggs in standing water. 6 This potential form of ver-
tical transmission within the viral reservoir may attribute to 
disease survival. Vertical transmission in this manner is 
certainly possible in tropical climates which the mosquitos 
currently inhabit and may also be a concern in adverse con-
ditions such as colder climates. 9 The mosquitos may lay eggs 
that will hatch once the environment becomes favorable.9,10 
The Aedes mosquitos typically exist in tropical climates, but 
their range has extended to include the southern United 
States, possibly allowing for local transmission in this area.6 
If a pregnant female becomes infected, she can pass the Zika 
virus to her fetus.6 Transmission may occur in utero or near 
the time of birth and may result in a wide range of health 
problems for the child. These could include microcephaly, 
decreased brain tissue, restricted joints, increased muscle 
tone or damage to the eyes. The Zika virus has been identi-
fied in breast milk; however, to date, there have not been any 
infections associated with breastfeeding. The proven benefits 
of breast milk currently outweigh the potential risk of Zika 
virus. Therefore, the CDC is still recommending breastfeed-
ing in areas where the virus is prevalent. 
An individual may also transmit the Zika virus to any sexual 
partners.6 Sexual transmission can occur before, during or 
after the infected individual develops symptoms. It has also 
been hypothesized that an asymptomatic carrier can still 
transmit the Zika virus to a sexual partner. The Zika virus has 
been identified in the semen for up to six months after the 
dissipation of symptoms, much longer than in the blood, 
urine and vaginal fluids. For this reason, the CDC is currently 
recommending the use of condoms for at least six months 
after a man has returned from an area where Zika virus is 
endemic or six months after he has received a positive diag-
nosis of Zika. 
Signs, Symptoms and Diagnosis 
The Zika virus can manifest itself in many ways once it in-
fects a host. A majority of those infected are asymptomatic or 
display mild symptoms such as low-grade fever, joint pain, 
maculopapular rash, arthralgia, nonpurulent conjunctivitis, 
headaches and myalgia.11,12 Approximately one in five pa-
tients initially asymptomatic will develop symptoms as late 
as 12 days after infection. In the asymptomatic population 
without detectable symptoms, the Zika virus can still be 
transmitted via blood primarily through blood transfusion 
and sexual intercourse.13 Typically, the Zika virus remains in 
the blood of an infected individual for about a week, but can 
remain in other fluids, such as semen, for much longer. If an 
individual suspects that he or she is infected with the Zika 
virus by displaying any of the above symptoms, he or she 
should immediately see their primary health care provider.12 
A number of factors should be examined in order to give an 
accurate diagnosis. Factors such as the patient's travel histo-
ry, symptoms and test results should be examined to deter-
mine if the patient is infected with Zika.14 Available diagnos-
tic tests include a blood (serum) test and a urine test, which 
are used to confirm the presence of the Zika virus in an indi-
viduaJ.12 Reverse transcription polymerase chain reaction 
(RT-PCR) tests are utilized to determine if a urine specimen 
is positive for Zika virus. Viral RNA in urine has been found 
to be positive as early as the first day of the onset of symp-
toms and as late as 20 days after onset of symptoms.is Serum 
samples may also be obtained to screen for viral RNA using 
polymerase chain reaction (PCR). If utilizing serum samples 
for diagnostic purposes, results are more accurate if obtained 
within seven days of symptom onset. Serum samples ob-
tained more than one week after symptom onset may not 
yield as accurate diagnostic results as urine samples. There-
fore, urine samples should be used for patients who present 
more than one week following onset of symptoms.12 Patients 
who present as asymptomatic or are unable to give a serum 
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or urine sample can undergo serology testing to confirm the 
presence of Zika. This test looks for the body's reaction 
against the virus in the form of antibodies that are present 
within a week of being exposed to the virus. Antibodies also 
remain in the patient's immune system months after infec-
tion. This serology testing is time-consuming and may not be 
specific to the Zika virus. Other viruses with similar struc-
tures, such as the yellow fever virus, may cross-react and 
result in a positive test. . 
A positive result may, in fact, represent a previous exposure 
to another virus or past vaccination, and therefore results 
are difficult to interpret.16 Although anyone is susceptible to 
Zika, testing should be reserved for individuals who have 
traveled to high-risk areas in which the Zika virus is known 
to be present. Special attention should be given to women 
who become pregnant within two months of returning from 
a high-risk area, and they should be tested even if they were 
originally asymptomatic. Likewise, all symptomatic patients 
with onset of Zika-like symptoms abroad or within 14 days 
of return should be offered both viral and serologic testing 
as part of a workup. There are a number of ways to detect 
Zika in a potentially infected or asymptomatic individuat.12 It 
is advised to attempt to gather a serum sample if possible, 
but urine testing is becoming more favorable, as Zika virus 
has been found up to 20 days after onset of symptoms. Fur-
ther investigations are needed to evaluate whether the live 
virus is excreted in urine. Although larger studies are needed 
for confirmation, current research strongly suggests that 
urine is a suitable specimen to be used to detect Zika in 
patients beyond 14 days after symptom onset.17 Urine speci-
mens are also likely suitable for use in epidemiologic investi-
gations of a larger scale such as testing returning travelers. 
Response from CDC/U.S. Food and Drug Administration 
(FDA)/National Institute of Allergy and Infectious Dis-
eases (NIAID) 
One of the main concerns to patients is the risk of severe 
fetal brain defects, such as microcephaly, associated with 
Zika virus infection.1s In response to this, the CDC has estab-
lished the US Zika Pregnancy Registry to collect information 
regarding the timing and risks associated with Zika virus 
infection and transmission during pregnancy. Patients who 
are eligible to be enrolled in the registry include pregnant 
women and their infants who have laboratory evidence of 
Zika virus infection, with or without symptomatology. This 
information will be used to update clinical recommendations 
for the treatment and prevention of Zika virus during preg-
nancy. 
Several health organizations are currently developing vac-
cines to target the Zika virus.19 One of these organizations, 
the National Institute of Allergy and Infectious Diseases 
(NIAID), is currently investigating several potential vaccine 
candidates. In a phase I clinical trial, a live-attenuated Zika 
vaccine based on the Dengue virus vaccine was shown to be 
safe and induce an immunologic response. This Dengue 
virus-based vaccine candidate is currently undergoing a 
large phase III study in Brazil. Dengue virus and Zika virus 
are both members of the flavivirus genus, and this similarity 
was the rationale behind investigating this particular vac-
cine. West Nile virus is also a member of the flavivirus ge-
nus,. Consequently, a deoxyribonucleic acid (DNA)-based 
vaccine for the Zika virus similar to the investigational vac-
cine for West Nile virus is also under investigation. This vac-
cine candidate is currently in an early stage trial. Another 
vaccine candidate includes a genetically engineered vesicu-
lar stomatitis virus (VSV). The VSV recombinant vaccine 
expresses the Zika virus E glycoprotein,20 and is therefore 
being evaluated for potential use in preventing Zika virus in 
tissue and animal models.19 Additionally, a whole-particle 
inactivated Zika vaccine based on Japanese encephalitis and 
Dengue virus vaccines is also being investigated. These vac-
cines are still in early developmental stages and are not ex-
pected to be available for several years. 
Current Management and Changes 
As the vaccines that are currently in development are still 
several years from FDA approval, current management of 
Zika consists of symptomatic treatment.21 This includes fluid 
replacement for dehydration, rest and acetaminophen for 
fever and pain. Due to the presence of similar symptomatolo-
gy between Zika virus and dengue fever, aspirin and other 
nonsteroidal anti-inflammatory drugs (NSAlDs) should be 
avoided until dengue can be ruled out. Administration of 
NSA!Ds to a patient with dengue fever significantly increases 
hemorrhaging. Differential diagnosis can be performed via a 
PCR test. 
Because there are no current antiviral medications or vac-
cines available to treat Zika virus, preventing transmission is 
an important counseling point.22 The most effective way to 
prevent the transmission of Zika virus is to avoid traveling to 
areas where Zika is present, when possible. If this is not pos-
sible, or the patient lives in an area where Zika is prevalent, 
he or she should exercise extreme caution to prevent mos-
quito bites. This includes wearing long-sleeved shirts and 
long pants that are treated with permethrin, staying in plac-
es with window and door screens, sleeping under a mosqui-
to bed net and using United States Environmental Protection 
Agency (EPA)-registered insect repellents. When using in-
sect repellents and sunscreen, it is important to apply the 
sunscreen before the insect repellent. Eliminating standing 
water is vital to prevent further reproduction of the Aedes 
species mosquitos responsible for the transmission of the 
Zika virus. Sexual transmission of Zika virus can be prevent-
ed by using condoms or abstaining from sex. At this time, the 
CDC is recommending that men who are exposed to Zika 
virus use condoms or abstain from sex for at least six months 
after returning from an area where Zika virus is present.23 
Women who are exposed to Zika virus should use these 
methods for at least eight weeks. Couples should be educat-
ed to use a reliable form of contraception to prevent the 
transmission of Zika virus from mother to fetus.22 
Conclusion 
As more information is discovered about the Zika virus, it is 
important for the public to remain informed about the virus 
demographics and possible treatments and vaccines. 
Understanding the virus's transmission, particularly through 
4 THE PHARMACY AND WELLNESS REVIEW Winter 2017 Volume 8, Issue 1 
Zika Virus: Infectious Process and Public Health Response Infectious Disease 
mosquito bites, sexual activity and from mother to fetus, is 
imperative for taking proper preventive measures. As a 
vaccine for the Zika virus is still several years away from 
availability, these precautions become even more important. 
Individuals who have traveled to Zika-infested areas or have 
a reason to suspect they may have been infected with the 
Zika virus should know the signs and symptoms of Zika and 
should understand when or if they should be tested for the 
virus. It is important for health care professionals to keep up 
to date as data emerges and recommendations change, so 
they can use this information to educate patients and ad-
dress concerns about the Zika virus. 
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Assessment Questions 
1. The first reports of locally transmitted Zika virus in the 
United States came from _ _ _ 
A. Houston, Texas 
B. Miami, Florida 
C. New Orleans, Louisiana 
D. San Diego, California 
2. After what major event did reports of Zika virus begin to 
surface in Brazil? 
A. 2014 FIFA World Cup 
B. Carnival in 2015 
C. 2016 Summer Olympics 
3. Which of the following has not been identified as a path-
way of transmission of the Zika virus? 
A. Sexual intercourse 
B. Respiratory droplets 
C. Mother to fetus 
D. Bite from a mosquito 
4. What are the CDC's recommendations on breastfeeding 
in areas where the Zika virus is prevalent? 
A. Zika has not been identified in breast milk, so 
breastfeeding is recommended. 
B. Zika has not been identified in breast milk, but 
breastfeeding should be avoided as a precaution. 
C. Zika has been identified in breast milk, so 
breastfeeding should be avoided. 
D. Zika has been identified in breast milk, but 
breastfeeding is recommended as the benefits 
outweigh the risks. 
5. A patient presents to your clinic suspecting they have 
symptoms of Zika. Upon questioning, you find they had 
travelled to Brazil and returned about a month ago, but 
have only had symptoms on and off for the past 17 days. 
Which of the following specimens could you test to 
determine ifthe patient is infected with Zika? 
1. Blood 
2. Urine 
3. Saliva 
4. Semen 
6. All of the following are potential symptoms for Zika ex-
cept~~~~~~~~~~~ 
A. Fever of 99.8° F 
B. Headache 
C. Constipation 
D. Muscle pain 
7. Which of the following is unlikely to put a patient at risk 
for contracting Zika? 
A. Traveling to Brazil or other areas known for 
outbreaks of Zika. 
B. Having a blood transfusion from a patient who 
had recently been in a high risk area for Zika. 
C. Not obtaining a proper medical workup after 
travelling to a high risk area. 
D. Travelling to areas known for outbreaks of the 
yellow fever virus. 
8. Investigational vaccines for Zika virus often mimic 
vaccines for which of the following infectious diseases 
due to their similarities? 
A. Human papilloma virus 
B. Influenza 
C. Herpes zoster 
D. Dengue fever 
9. Appropriate treatment for Zika virus includes which of 
the following? 
A. acyclovir 
B. acetaminophen 
C. ibuprofen 
D. Oseltamivir 
10. At a minimum, how long should a couple wait before 
trying to conceive a child if the man has recently traveled 
to an area infected with Zika virus? 
A. Eight weeks 
B. Oneyear 
C. Six months 
D. If symptomatic, until symptoms resolve, 
otherwise eight weeks. 
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